Eczema Pipeline 2025: Groundbreaking Clinical Advancements by 100+ Global Leaders - DelveInsight | Featuring Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, A

With Eczema reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Eczema pipeline comprises 100+ pharmaceutical and biotech companies actively developing 100+ therapeutic candidates targeting Eczema. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Eczema Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Eczema Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Eczema Drug Development @ https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Eczema Pipeline Report

DelveInsight's Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
As of May 2025, there have been significant developments in the treatment of eczema, particularly with the FDA's approval of new therapies aimed at improving patient outcomes.
On April 18, 2025, the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older who remain symptomatic despite antihistamine treatment. This approval marks Dupixent as the first new targeted therapy for CSU in over a decade, providing a new option for patients with this chronic skin condition.
In September 2024, the FDA approved EbglyssTM (lebrikizumab), a monoclonal antibody targeting interleukin-13, for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older. This approval offers an alternative treatment for individuals with eczema who have not responded adequately to other therapies .
Key Eczema companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others are evaluating new drugs for Eczema to improve the treatment landscape.
Promising Eczema pipeline therapies in various stages of development include Amlitelimab, BX 005, LP 0145, and others.

Eczema Overview:

Eczema, or atopic dermatitis, is a common skin condition marked by dry, itchy skin that may become inflamed or infected. It typically begins in childhood but can also affect adults. The condition is linked to genetic and environmental factors and is often called "the itch that rashes," as scratching can worsen symptoms. Common signs include red, dry patches-often on the cheeks, elbows, knees, hands, or feet-that may blister, or bleed.

Hydration is key to managing eczema, with topical steroids used for flare-ups. About 15-30% of children and 2-10% of adults are affected, with most cases starting in the first year of life. Symptoms can disrupt sleep and daily activities. Allergists can help manage eczema, especially when allergies are a trigger. Treatment may include moisturizers, ointments, antihistamines, and avoiding irritants like wool, soaps, and allergens such as dust, pets, or pollen.

Download the Eczema sample report to know in detail about the Eczema treatment market @ https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Eczema Pipeline Analysis
The Eczema pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Eczema Market.

Categorizes Eczema therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Eczema drugs under development based on:

Stage of development

Eczema Route of administration

Target receptor

Monotherapy vs. combination therapy

Eczema Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Eczema Licensing agreements

Funding and investment activities supporting future Eczema market advancement.

Unlock key insights into emerging Eczema therapies and market strategies here: https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Eczema Emerging Drugs

Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody targeting OX40L to rebalance the immune system by reducing pro-inflammatory T cells and boosting anti-inflammatory regulatory T cells, without broadly suppressing immunity. In Phase I trials, it effectively blocked T cell-driven skin inflammation and was well tolerated. Its immune-modulating action shows promise for various autoimmune diseases. Currently, Amlitelimab is in Phase II trials for treating eczema.

BX 005: BiomX

BX005 is a topical phage cocktail designed to target Staphylococcus aureus (S. aureus), a bacterium linked to the disease. In preclinical in vitro studies, BX005 demonstrated activity against over 90% of S. aureus strains isolated from skin samples in the U.S. and Europe, including antibiotic-resistant strains. The drug is currently in Phase I/II clinical trials for the treatment of atopic dermatitis.

LP 0145: LEO Pharma

LP 0145 is an anti-inflammatory monoclonal antibody being developed for atopic dermatitis. It is currently in Phase II clinical trials for the treatment of eczema.

Eczema Pipeline Therapeutic Assessment

Eczema Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Eczema By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Eczema Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Eczema Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Eczema therapies and key Eczema companies: https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Eczema Current Treatment Patterns
4. Eczema - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Eczema Late-Stage Products (Phase-III)
7. Eczema Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Eczema Discontinued Products
13. Eczema Product Profiles
14. Eczema Key Companies
15. Eczema Key Products
16. Dormant and Discontinued Products
17. Eczema Unmet Needs
18. Eczema Future Perspectives
19. Eczema Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Eczema pipeline reports offerings: https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.